Your browser doesn't support javascript.
loading
Orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting CD8+ T cells.
Corria-Osorio, Jesus; Carmona, Santiago J; Stefanidis, Evangelos; Andreatta, Massimo; Ortiz-Miranda, Yaquelin; Muller, Tania; Rota, Ioanna A; Crespo, Isaac; Seijo, Bili; Castro, Wilson; Jimenez-Luna, Cristina; Scarpellino, Leonardo; Ronet, Catherine; Spill, Aodrenn; Lanitis, Evripidis; Romero, Pedro; Luther, Sanjiv A; Irving, Melita; Coukos, George.
Affiliation
  • Corria-Osorio J; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne; and Department of Oncology, Lausanne University Hospital, Epalinges, Switzerland. angeldejesus.corriaosorio@unil.ch.
  • Carmona SJ; AGORA Cancer Research Center, Lausanne, Switzerland. angeldejesus.corriaosorio@unil.ch.
  • Stefanidis E; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne; and Department of Oncology, Lausanne University Hospital, Epalinges, Switzerland.
  • Andreatta M; AGORA Cancer Research Center, Lausanne, Switzerland.
  • Ortiz-Miranda Y; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne; and Department of Oncology, Lausanne University Hospital, Epalinges, Switzerland.
  • Muller T; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne; and Department of Oncology, Lausanne University Hospital, Epalinges, Switzerland.
  • Rota IA; AGORA Cancer Research Center, Lausanne, Switzerland.
  • Crespo I; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne; and Department of Oncology, Lausanne University Hospital, Epalinges, Switzerland.
  • Seijo B; AGORA Cancer Research Center, Lausanne, Switzerland.
  • Castro W; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne; and Department of Oncology, Lausanne University Hospital, Epalinges, Switzerland.
  • Jimenez-Luna C; AGORA Cancer Research Center, Lausanne, Switzerland.
  • Scarpellino L; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne; and Department of Oncology, Lausanne University Hospital, Epalinges, Switzerland.
  • Ronet C; AGORA Cancer Research Center, Lausanne, Switzerland.
  • Spill A; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne; and Department of Oncology, Lausanne University Hospital, Epalinges, Switzerland.
  • Lanitis E; AGORA Cancer Research Center, Lausanne, Switzerland.
  • Romero P; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne; and Department of Oncology, Lausanne University Hospital, Epalinges, Switzerland.
  • Luther SA; AGORA Cancer Research Center, Lausanne, Switzerland.
  • Irving M; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne; and Department of Oncology, Lausanne University Hospital, Epalinges, Switzerland.
  • Coukos G; AGORA Cancer Research Center, Lausanne, Switzerland.
Nat Immunol ; 24(5): 869-883, 2023 05.
Article de En | MEDLINE | ID: mdl-37081150
Sujet(s)
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Immunothérapie adoptive / Interleukine-2 / Lymphocytes T CD8/ / Tumeurs expérimentales Limites: Animals Langue: En Journal: Nat Immunol Sujet du journal: ALERGIA E IMUNOLOGIA Année: 2023 Type de document: Article Pays d'affiliation: Suisse Pays de publication: États-Unis d'Amérique
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Immunothérapie adoptive / Interleukine-2 / Lymphocytes T CD8/ / Tumeurs expérimentales Limites: Animals Langue: En Journal: Nat Immunol Sujet du journal: ALERGIA E IMUNOLOGIA Année: 2023 Type de document: Article Pays d'affiliation: Suisse Pays de publication: États-Unis d'Amérique